Ernexa Therapeutics Inc.
ERNA · XNASCIK 748592fmd_117D5EGCJ260DR1WHDKHZHRXG0Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2026, 66 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 22 | 21 | 23 | 20 | 6 | – | 0 | 0 | 1 | – |
| Cost of revenue | – | – | – | – | – | – | 0 | 0 | 0 | – |
| Gross profit | – | – | – | – | – | – | 0 | (0) | 0 | – |
| Research and development | – | 0 | 0 | 0 | 4 | 13 | 10 | 6 | 5 | 4 |
| Selling, general and administrative | 16 | 16 | 14 | 13 | 8 | – | – | – | – | – |
| Total operating expenses | 25 | 23 | 23 | 22 | 7 | 114 | 33 | 21 | 16 | 9 |
| Operating income | (2) | (1) | 0 | (2) | (7) | (114) | (33) | (21) | (16) | (9) |
| Interest expense | 1 | 0 | 0 | 0 | 0 | – | 0 | 1 | (7) | (0) |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (1) | 0 | (1) | (0) | (0) | (9) | 9 | (1) | (29) | (5) |
| Income before taxes | (3) | (1) | (0) | (2) | (7) | (122) | (25) | (22) | (45) | (14) |
| Income tax expense | 0 | 0 | (0) | 0 | 0 | 0 | 0 | (0) | 0 | (0) |
| Net income from continuing operations | (3) | (1) | (0) | (2) | (7) | (123) | (25) | (22) | (45) | (14) |
| Net income | (3) | (1) | (0) | (2) | (7) | (123) | (25) | (22) | (45) | (14) |
| Net income to common shareholders | – | (1) | (0) | (2) | (7) | (123) | (25) | (22) | (45) | (14) |